newsfilter
← Latest News
Business Wire·

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Realigning resources to extend runway to mid-2027 Focus on clinical development of RP-1664 (PLK4 inhibitor) and RP-3467 (Polθ ATPase inhibitor), with initial clinical readouts expected beginning in Q3 2025 Exploring